Clinical Trial

Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

Study acronym: ADAPT
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 13, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The brief purpose of this research study is to learn about the safety, tolerability, and efficacy of paraspinal intramuscular injection of CELZ-201-DDT in patients with chronic lower back pain.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-09-21; most recent amendment 2026-02-11.
Status change: Not Yet Recruiting → Recruiting 2024-05-30
Trial Details
NCT Number NCT06053242
Lead Sponsor Creative Medical Technology Holdings Inc
Conditions Chronic Low-back Pain, Degenerative Disc Disease
Enrollment 45 participants
Start Date 2024-05-21
Primary Completion 2026-05-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-13